### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form NT 10-Q

#### BIODELIVERY SCIENCES INTERNATIONAL INC

Form NT 10-Q August 15, 2002

## SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 12b-25

Commission File Number 0-28931

#### NOTIFICATION OF LATE FILING

(Check	One):	[_] Form 10-F		-K [_] Form 20	0-F [X] Form 10-Q
	For P	eriod Ended:	June 30, 2002		
[_ [_ _]	_] Trans _] Trans _] Trans _] Trans	ition Report ition Report ition Report ition Report	on Form 11-K on Form 10-Q on Form N-SAR		
Read attached instruction sheet before preparing form. Please print or type.					
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.					
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:					

## PART I REGISTRANT INFORMATION

BioDelivery Sciences International, Inc.

\_\_\_\_\_

Full name of registrant

University of Medicine and Dentistry
New Jersey Medical School
Administrative Bldg #4
185 South Orange Avenue
Newark, NJ 07103

Address of principal executive office (Street and number)

# PART II RULE 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule  $12b-25\,(b)$ , the

#### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form NT 10-Q

following should be completed. (Check box if appropriate.)

- (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- | (b) The subject annual report, semi-annual report, transition report
  | on Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will
  | be filed on or before the 15th calendar day following the
  | prescribed due date; or the subject quarterly report or
  | transition report on Form 10-Q, or portion thereof will be filed
  | on or before the fifth calendar day following the prescribed due
  | date; and
  - (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

#### PART III NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

Additional detailed information needed from public offering; EDGAR deadline missed by one-half hour.

### PART IV OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

James A. McNulty, CPA (Chief Financial Officer) 813-902-8980

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

[X] Yes [\_] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

[ ] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

BioDelivery Sciences International, Inc.
----(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned

### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form NT 10-Q

thereunto duly authorized.

Date August 15, 2002 By /s/ James A. McNulty

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

#### ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (see 18 U.S.C. 1001).